CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Novartis Pharmaceuticals Corporation v. West-Ward Pharmaceuticals International Limited

1:15-cv-00474

Overview

Case Number 1:15-cv-00474
Filing Date 2015-06-10
Status Terminated
Termination Date 2017-12-21
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand None

Parties

Defendant

West-Ward Pharmaceuticals International Limited NPE (University / Research)

Represented By

14 Attorneys Listed

Natasha E. Daughtrey

Email: ndaughtrey@goodwinlaw.com

Naomi L. Birbach

Email: nbirbach@goodwinlaw.com

Kevin M. Nelson

Email: kevin.nelson@afslaw.com

Kelly E. Farnan

Richards, Layton & Finger, PA

Tel: +1 (302) 651-7705

Richards, Layton & Finger, PA, One Rodney Square

Joel M. Wallace

Email: joel.wallace@afslaw.com

Imron T. Aly

Email: imron.aly@afslaw.com

David Ellis Moore

Potter Anderson & Corroon, LLP

Tel: +1 (302) 984-6000

1313 N. Market St., Hercules Plaza, 6th Flr., P.O. Box 951

Marta E. Gross

Email: mgross@goodwinprocter.com

Keith A. Zullow

Email: kzullow@goodwinlaw.com

Michael B. Cottler

Email: mcottler@goodwinlaw.com

Steven J. Bernstein

Email: sbernstein@goodwinlaw.com

Timothy J. Doyle

Email: tdoyle@bakerlaw.com

Cindy Chang

Email: cindychang@goodwinlaw.com

Bindu Ann George Palapura

Potter Anderson & Corroon, LLP

Tel: +1 (302) 984-6000
Fax: +1 (302) 778-6000

1313 N. Market St., Hercules Plaza, 6th Flr., P.O. Box 951

Novartis AG Operating Company

Represented By

4 Attorneys Listed

Susanne L. Flanders

Email: sflanders@venable.com

Jared L. Stringham

Email: jlstringham@venable.com

Daniel M. Silver

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 691-1260

Renaissance Centre, 405 N. King Street, 8th Floor

Benjamin A. Smyth

McCarter & English, LLP

Tel: +1 (302) 984-6300

Renaissance Centre, 405 N. King Street, 8th Floor

Novartis Pharmaceuticals Corporation Operating Company

Represented By

6 Attorneys Listed

Susanne L. Flanders

Email: sflanders@venable.com

Jared L. Stringham

Email: jlstringham@venable.com

Daniel M. Silver

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 691-1260

Renaissance Centre, 405 N. King Street, 8th Floor

Nicholas N. Kallas

Email: nkallas@venable.com

Christina Schwarz

Email: cschwarz@venable.com

Benjamin A. Smyth

McCarter & English, LLP

Tel: +1 (302) 984-6300

Renaissance Centre, 405 N. King Street, 8th Floor

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360° Radar 11 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

🇺🇸
U.S. District Courts Counterparts in force
🏛️
USPTO PTAB Trials 6 proceedings
🇪🇺
Unified Patent Court (UPC) Counterparts in force
🇩🇪
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (11): 🇪🇺 Europe GB 🇺🇸 US 🌐 PCT
Parallel Proceedings Across Jurisdictions (6 found):
PTAB: 6
USPTO PTAB Trial 2018-01-17
IPR2018-00507

Hikma Pharmaceuticals PLC v. Novartis Pharmaceuticals Corporation

U.S. Continuation Sibling (8410131)
Status: Terminated-Settled
USPTO PTAB Trial 2017-06-12
IPR2017-01592

Breckenridge Pharmaceutial, Inc. v. Novartis Pharmaceuticals Corporation

U.S. Continuation Sibling (8410131)
Status: Terminated-Settled
USPTO PTAB Trial 2017-03-13
IPR2017-01078

West-Ward Pharmaceuticals International Limited v. Novartis AG

Asserted Patent
Status: Terminated-Settled
USPTO PTAB Trial 2017-03-10
IPR2017-01063

Argentum Pharmaceuticals LLC et al. v. Novartis AG

Asserted Patent
Status: Final Written Decision
USPTO PTAB Trial 2016-07-22
IPR2016-01479

Par Pharmaceutical, Inc. et al. v. Novartis AG

Asserted Patent
Status: Final Written Decision
USPTO PTAB Trial 2016-07-19
IPR2016-01461

Roxane Laboratories, Inc. et al. v. Novartis AG

Asserted Patent
Status: Institution Denied
Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

2 Patents

There are 2 patents involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US9006224
Neuroendocrine tumor treatment
Filed: 2006-11-20
Issued: 2015-04-14
Active (1.6 yrs remaining) +589d PTA
Expires: 2028-07-01
US8410131
Cancer treatment
Filed: 2002-02-18
Issued: 2013-04-02
Expired (Term Ended) +1352d PTA
Expires: 2025-11-01

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. § 283) Active Threat

Active Threat — Patent is within enforceable statutory term; injunctive relief viable.

Terminal Disclaimer & Cellect Risk Scrutiny / Risk

High PTA (+589 days) / In re Cellect scrutiny applies.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. § 286, damages cannot accrue for infringement prior to 6 years before filing. 4th & 8th Year Maintenance Fees Paid (12th Year Window Upcoming).

Procedural Motions & Interlocutory Orders

Motion Intelligence

Total Motions

5

Dispositive

0

Granted

0

Denied

0

Pending / Review

5

Motions by Category

Claim Construction / Markman Filing 3 Procedural / Extension Motion 2

Key Dispositive Motions & Rulings

Procedural / Extension Motion Pending / Under Review
Second STIPULATION TO EXTEND TIME to complete expert depositions to March 17, 2017 - filed by Novartis AG, Novartis Pharmaceuticals Corporation. (Silver, Daniel...
Entry #50 • 2017-02-08 Document →
Procedural / Extension Motion Pending / Under Review
STIPULATION TO EXTEND TIME Rebuttal and Reply Expert Reports to See Stip for Details - filed by Novartis AG, Novartis Pharmaceuticals Corporation. (Smyth, Benja...
Entry #47 • 2016-11-09 Document →
Claim Construction / Markman Filing Pending / Under Review
Letter to The Honorable Richard G. Andrews from Daniel M. Silver, Esq. regarding Markman Hearing. (Silver, Daniel) (Entered: 04/15/2016)
Entry #31 • 2016-04-15 Document →
Claim Construction / Markman Filing Pending / Under Review
ORAL ORDER: Per the representations in the Letter at D.I. 31, the Markman hearing set for 6/23/2016, is now CANCELED. Ordered by Judge Richard G. Andrews on 4/1...
Entry #32 • 2016-04-15 Document →
Claim Construction / Markman Filing Pending / Under Review
SCHEDULING ORDER: Case referred to the Magistrate Judge for the purpose of exploring ADR. Joinder of Parties due by 5/31/2016. Amended Pleadings due by 5/31/201...
Entry #19 • 2015-11-24 Document →

Docket Entries

(63 total)
Pleading / Complaint

COMPLAINT filed against Roxane Laboratories Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-1736956.) - filed by Novartis Pharmaceuticals Corporation, Novartis AG. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Civil Cover Sheet)(sar) (Entered: 06/10/2015)

Entry #1 • 2015-06-10
1
Pleading / Complaint

COMPLAINT filed against Roxane Laboratories Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-1736956.) - filed by Novartis Pharmaceuticals Corporation, Novartis AG. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Civil Cover Sheet)(sar) (Entered: 06/10/2015)

Entry #1 • 2015-06-10
2
Pleading / Complaint

COMPLAINT filed against Roxane Laboratories Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-1736956.) - filed by Novartis Pharmaceuticals Corporation, Novartis AG. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Civil Cover Sheet)(sar) (Entered: 06/10/2015)

Entry #1 • 2015-06-10
2
Pleading / Complaint

COMPLAINT filed against Roxane Laboratories Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-1736956.) - filed by Novartis Pharmaceuticals Corporation, Novartis AG. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Civil Cover Sheet)(sar) (Entered: 06/10/2015)

Entry #1 • 2015-06-10
2

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (sar) (Entered: 06/10/2015)

Entry #2 • 2015-06-10
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc